Business context and reporting period
This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2022. The registrant is TradeUP Acquisition Corp., a blank-check company and shell company—not yet the combined Estrella Immunopharma business. It had no operating revenue and had not commenced operations. Its activities were limited to public-company costs and searching for and pursuing a business combination.
On September 30, 2022, TradeUP entered into a merger agreement with Estrella Biopharma, Inc., a preclinical-stage cell-therapy company. At closing, Estrella would become a wholly owned subsidiary and the combined company would be named Estrella Immunopharma, Inc. The filing describes the transaction as proposed, not completed.
Financial performance and position
- Revenue and margins: No operating revenue; operating margins are not meaningful. The company expects no operating revenue before a business combination.
- Net loss: $344,863 for Q3 2022, versus $107,547 for Q3 2021. For the first nine months of 2022, net loss was $845,701, versus $111,921 from inception through September 30, 2021; the latter is not a like-for-like nine-month comparison.
- Q3 expense drivers: Formation and operating costs of $523,518 and franchise taxes of $25,658, partly offset by $204,313 of trust-account dividends. Nine-month figures were $1,044,023, $73,858 and $272,180, respectively.
- Cash flow: Operating cash use was $903,716 in the first nine months of 2022. No investing cash flow was reported for that period; financing provided $498,600 from related-party notes. Cash decreased by $405,116 to $73,752.
- Assets and liquidity: Total assets were $45.62 million, including $45.46 million in the trust account, versus total liabilities of $2.29 million. Working capital deficit was $575,002. Trust funds are primarily reserved for the business combination or public-share redemptions and are not ordinary operating liquidity.
- Debt and obligations: The company had $498,600 outstanding under unsecured, non-interest-bearing related-party notes, payable at the earlier of the business combination or maturity; lenders may elect conversion at $10 per share. A further $1.55 million deferred underwriters’ fee is payable upon a completed business combination. The company reported no long-term debt or lease obligations.
Material changes and transaction developments
- Q3 net loss increased from the prior-year quarter, chiefly reflecting higher formation and operating costs; trust-account dividends also increased.
- The merger agreement provides Estrella stockholders aggregate consideration of $325 million in newly issued company shares, calculated at $10 per share, subject to the agreement’s terms. A registration statement on Form S-4 was filed October 17, 2022.
- The company’s business-combination deadline was January 19, 2023. If no combination is completed by then, it must cease operations, redeem public shares from the trust account and liquidate, subject to applicable requirements; warrants would expire worthless.
Outlook, risks and unusual items
- Going concern: Management said the low cash balance, working capital deficit, ongoing costs and looming combination deadline raise substantial doubt about the company’s ability to continue as a going concern. Its plans rely on related-party notes and potential working-capital loans; success in completing a combination by the deadline was not assured.
- Control weakness: Management concluded disclosure controls were ineffective as of September 30, 2022, citing a material weakness in accounting for complex equity instruments and a restatement related to redeemable-share classification. It described plans for additional training and review.
- Redemption-related tax risk: A new federal 1% excise tax could apply to certain stock repurchases or redemptions after December 31, 2022, potentially reducing cash available for a transaction.
- Other disclosures: The company reported no material legal proceedings and no material changes to previously disclosed risk factors. It noted potential COVID-19 effects were not readily determinable. No specific financial guidance was provided.
Important facts for investors to verify
- Current status, conditions and expected timing of the proposed merger, including shareholder approval, redemptions, financing and final transaction documentation.
- Available cash outside the trust account, further related-party funding and the consequences if the January 19, 2023 deadline is not met.
- The S-4’s complete pro forma capitalization, dilution, ownership and redemption scenarios, and any transaction-related financing.
- Details and remediation progress for the material weakness and the redeemable-share classification restatement.
- The amount and treatment of any excise tax, deferred underwriters’ fee and other transaction costs at closing.